NEWS & CONTENT
Where COMED's Work Becomes Public Record
Milestones, data, publications, and recognition; a running record of COMED's progress, from grant approvals to conference stages.
Presenting Our Pancreatic Cancer Work at CRIHM’s First Stakeholders’ Meeting
COMED presents first-in-class KRAS G12V targeting at Pancreatic Cancer Europe’s 10th anniversary Masterclass for healthcare professionals.
Malaria Program Completes Computational Design Phase, Backed by Xjenza Malta
COMED completes the computational design phase of its malaria antibody program, backed by Xjenza Malta and published in the journal Gene.
Presenting First-in-Class KRAS G12V Targeting at Pancreatic Cancer Europe’s 10th Anniversary Masterclass
Full in vivo data confirm COMED Hooks suppresses tumor growth in a pancreatic cancer model, with 100% survival and strong tolerability.
The Full Picture: In Vivo Data Confirm COMED Hooks Suppress Tumor Growth
Full in vivo data confirm COMED Hooks suppresses tumor growth in a pancreatic cancer model, with 100% survival and strong tolerability.